Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update
Files
Publication date
2018-01-09
Authors
Amstutz, Ursula
Henricks, Linda M
Offer, Steven M
Barbarino, Julia
Schellens, Jan H M
Swen, Jesse J.
Klein, Teri E
McLeod, Howard L
Caudle, Kelly E
Diasio, Robert B
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
Abstract
The purpose of this guideline is to provide information for the interpretation of clinical dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be used to guide dosing of fluoropyrimidines (5-fluorouracil and capecitabine). Detailed guidelines for the use of fluoropyrimidines, their clinical pharmacology, as well as analyses of cost-effectiveness are beyond the scope of this document. The Clinical Pharmacogenetics Implementation Consortium (CPIC®) guidelines consider the situation of patients for which genotype data are already available (updates available at https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/).
Keywords
Citation
Amstutz, U, Henricks, L M, Offer, S M, Barbarino, J, Schellens, J H M, Swen, J J, Klein, T E, McLeod, H L, Caudle, K E, Diasio, R B & Schwab, M 2018, 'Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing : 2017 Update', Clinical Pharmacology and Therapeutics, vol. 103, no. 2, pp. 210-216. https://doi.org/10.1002/cpt.911